Bosentan · Tracleer

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Systemic Sclerosis · Phase 3 · investigational in the US

Also approved (2)
JP
  • All forms of pulmonary arterial hypertension
Product first approved 2005thepharmaletter.com
EU
  • Pulmonary arterial hypertension (WHO functional class III); reduction of new digital ulcers in systemic sclerosis
Product first approved 2002EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (25)
Pulmonary Arterial Hypertension
NCT04039464 · Johns Hopkins University
2022-08-01 – 2025-12-31 · Pediatric Pulmonary Hypertension
What this study did
NCT01338415 · Actelion
2011-03-08 – 2020-05-29 · Pulmonary Arterial Hypertension
What this study did
NCT01223352 · Actelion
2011-03-08 – 2013-08-19 · Pulmonary Arterial Hypertension
What this study did
NCT01392469 · Novartis Pharmaceuticals
2011-04-20 – 2012-10-25 · Pulmonary Arterial Hypertension
What this study did
NCT00319020 · Actelion
2005-08-23 – 2011-10-28 · Pulmonary Arterial Hypertension
What this study did
NCT00864201 · Hamilton Health Sciences Corporation
2009-04 – 2010-04 · Hypertension, Pulmonary, Connective Tissue Disease
What this study did
NCT00302211 · Actelion
2006-02-01 – 2008-07-01 · Pulmonary Hypertension
What this study did
NCT00310830 · Actelion
2006-03 – 2007-08 · Pulmonary Hypertension
What this study did
Systemic Sclerosis
Other / comorbidity
NCT02377271 · University Hospital, Grenoble
2015-08 – 2027-02 · Ischemic Optic Neuropathy
What this study did
NCT03841734 · Centre Hospitalier Universitaire de Nice
2020-02-04 – 2023-07-26 · Arteritis, Giant Cell, Blindness and Low Vision
What this study did
NCT00820352 · University Teaching Hospital Hall in Tirol
2009-01 – 2014-06 · Heart Failure, Diastolic, Hypertension, Pulmonary
What this study did
NCT01218607 · Universitaire Ziekenhuizen KU Leuven
2010-10 – 2014-03 · Heart Septal Defects, Atrial
What this study did
NCT01389856 · Actelion
2011-12 – 2014-01 · Persistent Pulmonary Hypertension of the Newborn
What this study did
NCT00638131 · Centre hospitalier de l'Université de Montréal (CHUM)
2009-01 – 2010-06 · Type 2 Diabetes
What this study did
NCT00631475 · Actelion
2008-04 – 2010-05 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00319111 · Actelion
2006-01 – 2009-04 · Pulmonary Hypertension
What this study did
NCT00319696 · Actelion
2004-07-08 – 2009-01-22 · Digital Ulcers
What this study did
NCT00303004 · Copenhagen University Hospital, Rigshospitalet
2006-03 – 2008-01 · Eisenmenger Syndrome
What this study did
NCT00360087 · Actelion
2006-03 – 2007-12 · Pulmonary Hypertension, Sickle Cell Anemia
What this study did
NCT00313196 · Actelion
2006-04 – 2007-08 · Pulmonary Hypertension
What this study did
NCT00313222 · Actelion
2005-10 – 2007-03 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
Phase 2/3 (5)
Pulmonary Arterial Hypertension
NCT00581607 · University of Cincinnati
2008-04 – 2012-12 · Sarcoidosis, Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01352065 · Center for Health Sciences, Serbia
2011-01 – 2013-05 · Pulmonary Hypertension
What this study did
NCT00071461 · Actelion
2003-08 – 2010-05 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00319033 · Actelion
2004-07 – 2006-02 · Interstitial Lung Disease, Scleroderma
What this study did
NCT00070590 · Actelion
2003-07 – 2005-09 · Pulmonary Fibrosis, Scleroderma, Systemic
What this study did
Phase 2 (19)
Pulmonary Arterial Hypertension
NCT01827059 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2013-10 – 2018-06 · Pulmonary Arterial Hypertension, Congenital Heart Disease
What this study did
NCT00825266 · Stanford University
2008-09 – 2010-05 · Hypertension, Pulmonary
What this study did
Systemic Sclerosis
NCT00377455 · Georgetown University
2006-09 – 2010-03 · Systemic Scleroderma, Pulmonary Hypertension
What this study did
NCT00318175 · Heinrich-Heine University, Duesseldorf
2006-06 – 2007-05 · Systemic Scleroderma, Skin Fibrosis, Hand Functionality
What this study did
Other / comorbidity
NCT06957002 · Assistance Publique - Hôpitaux de Paris
2026-06 – 2030-06 · Giant Cell Arteritis (GCA)
What this study did
NCT06887062 · University of Edinburgh
2025-03-21 – 2027-07-01 · Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
What this study did
NCT04388124 · University Hospital, Rouen
2021-10-20 – 2026-08 · Resistant Hypertension
What this study did
NCT01241383 · Assistance Publique - Hôpitaux de Paris
2010-12-06 – 2016-06 · Scleroderma Renal Crisis
What this study did
NCT01617746 · University of Glasgow
2012-11 – 2015-12 · Asthma
What this study did
NCT02093195 · Air Force Military Medical University, China
2013-12 – 2015-12 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02317679 · Centre Hospitalier Universitaire de Nice
2014-04 – 2015-02 · Port-wine Stains
What this study did
NCT01518595 · Medical University of Vienna
2011-10 – 2014-04 · Hepatopulmonary Syndrome, Liver Cirrhosis
What this study did
NCT01292551 · Copenhagen University Hospital, Rigshospitalet
2011-02 – 2013-03 · Hypoplastic Left Heart Syndrome, Tricuspid Atresia, Other Specified Congenital Anomalies of Heart
What this study did
NCT01662037 · Shanghai Jiao Tong University School of Medicine
2010-01 – 2012-06 · Congenital Heart Defects, Functional Single Ventricle
What this study did
NCT00777985 · University Hospital, Grenoble
2007-12 – 2012-01 · Obstructive Sleep Apnea, Hypertension
What this study did
NCT01357109 · Karolinska Institutet
2007-11 – 2011-01 · Type 2 Diabetes Mellitus
What this study did
NCT00815347 · UConn Health
2008-12 – 2010-09 · Asthma
What this study did
NCT00926627 · Daniel Doberer
2009-04 – 2010-03 · Sarcoidosis, Pulmonary Hypertension
What this study did
NCT01009177 · Actelion
2005-09-30 – 2008-02-29 · Melanoma
What this study did
Phase 1/2 (2)
Systemic Sclerosis
NCT00226889 · Rikshospitalet University Hospital
2005-01 – 2009-06 · Systemic Sclerosis (Scleroderma)
What this study did
Other / comorbidity
NCT01270750 · General Hospital of Chalkida
2010-12 – 2011-06 · SECONDARY PULMONARY HYPERTENSION, MITRAL STENOSIS, CHILDHOOD RHEUMATOID FEVER, CONGESTIVE HEART FAILURE
What this study did
Phase 1 (18)
Pulmonary Arterial Hypertension
NCT06484673 · Humanis Saglık Anonim Sirketi
2024-04-21 – 2024-05-27 · Pulmonary Arterial Hypertension
What this study did
NCT04991207 · Bial - Portela C S.A.
2018-02-06 – 2018-05-14 · Pulmonary Arterial Hypertension
What this study did
NCT01100736 · University of Edinburgh
2009-01 – 2010-01 · Pulmonary Arterial Hypertension, Vasodilation, Vasoconstriction
What this study did
Other / comorbidity
NCT04158635 · City of Hope Medical Center
2021-09-01 – 2027-03-09 · Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
What this study did
NCT07649941 · Boehringer Ingelheim
2026-06-22 – 2026-08-24 · Healthy
What this study did
NCT07838987 · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2023-12-21 – 2026-06-30 · Healthy
What this study did
NCT07081932 · Boehringer Ingelheim
2025-08-26 – 2025-10-08 · Healthy
What this study did
NCT05657613 · CTI BioPharma
2023-01-03 – 2023-06-08 · Drug Interactions
What this study did
NCT05723874 · Boehringer Ingelheim
2023-03-06 – 2023-05-26 · Healthy
What this study did
NCT04068272 · Retinset SL
2019-09-07 – 2022-05-20 · Diabetes Mellitus
What this study did
NCT04770155 · University of Mississippi Medical Center
2021-05-27 – 2021-09-20 · Vascular Function, Racial Disparity
What this study did
NCT05146089 · University of Missouri-Columbia
2016-12-20 – 2021-04-12 · Sleep Apnea, Healthy, Vasoconstriction, Vasodilation
What this study did
NCT00223717 · Vanderbilt University
2001-01 – 2017-01 · Hypertension
What this study did
NCT02667704 · Boehringer Ingelheim
2016-02 – 2016-03 · Healthy
What this study did
NCT01929213 · Dong-A Pharmaceutical Co., Ltd.
2013-08 – 2014-02 · Healthy Volunteers
What this study did
NCT00260819 · Assistance Publique - Hôpitaux de Paris
2006-01 – 2008-04 · Hypoxia-Induced Pulmonary Artery Hypertension
What this study did
NCT00701597 · Medical University of Vienna
2007-04 – 2007-10 · Glaucoma, Blood Flow Velocity
What this study did
NCT00432978 · VA Loma Linda Health Care System
2006-07 – 2007-02 · Altitude, Pulmonary Hypertension
What this study did
Phase 4 (20)
Pulmonary Arterial Hypertension
NCT03053739 · Post Graduate Institute of Medical Education and Research, Chandigarh
2016-12 – 2017-12 · Associated Pulmonary Arterial Hypertension
What this study did
NCT03236818 · Amsterdam UMC, location VUmc
2013-05 – 2017-09 · Pulmonary Arterial Hypertension
What this study did
NCT00303459 · Actelion
2006-05 – 2013-12 · Pulmonary Arterial Hypertension
What this study did
NCT00323297 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-09 – 2013-08 · Pulmonary Arterial Hypertension
What this study did
NCT00433329 · Actelion
2007-03 – 2010-08 · Pulmonary Arterial Hypertension
What this study did
NCT00625469 · Rajan Saggar
2007-10 – 2009-12 · Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
What this study did
NCT00266162 · Competence Network for Congenital Heart Defects
2004-08 – 2008-02 · Eisenmenger Syndrome
What this study did
NCT00367770 · Actelion
2004-01 – 2005-12 · Pulmonary Arterial Hypertension
What this study did
NCT00317486 · Actelion
2003-09 – 2005-04 · Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
What this study did
Systemic Sclerosis
NCT02480335 · University Medical Center Groningen
2015-06-26 – 2018-07-30 · Scleroderma, Systemic
What this study did
NCT01395732 · Actelion
2011-03-31 – 2012-12-31 · Systemic Sclerosis, Digital Ulcers
What this study did
Other / comorbidity
NCT03229694 · Xuzhou Medical University
2017-08-01 – 2018-05-01 · Tourniquets, Hypertension, Bosentan
What this study did
NCT01779596 · Radboud University Medical Center
2011-05 – 2013-12 · Type 2 Diabetes Mellitus
What this study did
NCT01779609 · Radboud University Medical Center
2010-04 – 2013-12 · Type 2 Diabetes Mellitus
What this study did
NCT01449253 · All India Institute of Medical Sciences
2011-08 – 2013-07 · Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia
What this study did
NCT00679068 · IRCCS Azienda Ospedaliero-Universitaria di Bologna
2008-05 – 2013-06 · Pulmonary Hypertension
What this study did
NCT00637065 · Royal Brompton & Harefield NHS Foundation Trust
2008-04 – 2010-08 · Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia
What this study did
NCT00595049 · Actelion
2006-05-31 – 2010-06-30 · Hypertension, Pulmonary
What this study did
NCT00082186 · Actelion
2003-07 – 2007-11 · Hypertension, Pulmonary
What this study did
Early phase / not applicable (9)
Pulmonary Arterial Hypertension
NCT01548950 · University of Sao Paulo General Hospital
2011-09 – 2020-03 · Congenital Heart Disease, Pulmonary Arterial Hypertension
What this study did
NCT00909337 · Medical University of Graz
2008-01 – 2010-06 · Pulmonary Hypertension, Systemic Sclerosis
What this study did
NCT01721564 · Prof David S Celermajer
2006-04 – 2009-12 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT02116335 · Augusta University
2015-06 – 2026-01 · Hypertension
What this study did
NCT01184404 · Berto J Bouma
2011-09 – 2016-07 · Congenital Heart Disease
What this study did
NCT01378845 · Christoph Hehrlein
2011-07 – 2015-09 · Raynaud's Phenomenon, Skin Necrosis
What this study did
NCT02389426 · Universitair Ziekenhuis Brussel
2014-12 – 2015-04 · Multiple Sclerosis
What this study did
NCT00989911 · University of California, Los Angeles
2010-05 – 2013-03 · Congenital Heart Disease
What this study did
NCT01738542 · Hospital Universitario Getafe
2009-04 – 2010-11 · Peripheral Arterial Disease
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Other / comorbidity
NCT04101370 · Geropharm
2018-05-24 – 2018-06-20 · Bioequivalence
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Pulmonary Arterial Hypertension
NCT01712997 · Air Force Military Medical University, China
2012-09 – 2014-09 · Pulmonary Arterial Hypertension
What this study did
Phase 1 (1)
Other / comorbidity
NCT05072106 · PharmaMar
2021-01-14 – 2022-01-18 · Advanced Solid Tumor
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bosentan (Tracleer): this drugApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Aprocitentan (Tryvio)
Approved(overall)
Small moleculeEndothelin receptor (ETA/ETB, dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tracleer (Bosentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 3Ischemic Optic NeuropathyActive not recruiting
Est. primary completion 2027-02 · NCT02377271 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu ArteritisRecruiting
Est. primary completion 2027-07-01 · NCT06887062 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 2Giant Cell Arteritis (GCA)Not yet recruiting
Est. primary completion 2029-06 · NCT06957002 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

November 2025ApprovalFDA updates Boxed Warning on Tracleer (NDA021290)
US, FDA · FDA · Source ↗